Clinical trial
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung…
NCT00125359 · Konstantin Dragnev, Other · Completed
Key facts
| NCT number | NCT00125359 |
|---|---|
| Title | Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer |
| Official title | A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer |
| Lead sponsor | Konstantin Dragnev, Other |
| Collaborators | Ligand Pharmaceuticals Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug |
| Interventions | erlotinib and bexarotene |
| Enrollment | 42 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2014 |
| First posted | Aug 1, 2005 |
| Last update posted | Jan 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: